Boston Scientific Corp (BSX): Kevin J. Ballinger , SVP & Pres, Interven Cardio of Boston Scientific Corp sold 78,122 shares on Jul 20, 2016. The Insider selling transaction was reported by the company on Jul 21, 2016 to the Securities and Exchange Commission. The shares were sold at $24.03 per share for a total value of $1,877,271.62 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jul 20, 2016, David A Pierce (SVP and President, Endoscopy) sold 2,480 shares at $24.03 per share price.On Jul 20, 2016, Michael P. Phalen (EVP & President, MedSurg) sold 35,000 shares at $24.03 per share price.Also, On Jul 5, 2016, Timothy A. Pratt (EVP, GC & Chief Admin Officer) sold 24,000 shares at $23.39 per share price.On Jul 5, 2016, Michael F Mahoney (President & CEO) sold 100,000 shares at $23.43 per share price.
Boston Scientific Corporation: On Wednesday, Jul 20, 2016 heightened volatility was witnessed in Boston Scientific Corporation which led to swings in the share price. The shares opened for trading at $24.04 and hit $24.45 on the upside , eventually ending the session at $24.26, with a gain of 2.15% or 0.51 points. The heightened volatility saw the trading volume jump to 1,08,68,362 shares. The 52-week high of the share price is $24.45 and the company has a market cap of $32,918 M . The 52-week low of the share price is at $14.1801.
Company has been under the radar of several Street Analysts.Boston Scientific Corporation is Initiated by Guggenheim to Buy. The Rating was issued on Jun 9, 2016.Boston Scientific Corporation is Reiterated by RBC Capital Mkts to Outperform and the brokerage firm has raised the Price Target to $ 25 from a previous price target of $22 .The Rating was issued on Apr 28, 2016.Boston Scientific Corporation is Reiterated by Stifel to Buy and the brokerage firm has raised the Price Target to $ 25 from a previous price target of $22 .The Rating was issued on Apr 28, 2016.Boston Scientific Corporation is Reiterated by Wedbush to Neutral and the brokerage firm has raised the Price Target to $ 23 from a previous price target of $19 .The Rating was issued on Apr 28, 2016.Boston Scientific Corporation is Reiterated by Barclays to Overweight and the brokerage firm has raised the Price Target to $ 25 from a previous price target of $23 .The Rating was issued on Apr 28, 2016.
Boston Scientific Corporation develops manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology which includes Drug-Eluting Coronary Stent Systems Intravascular Imaging devised and Coronary Technology products such as guide wires guide catheters and balloon catheters among others; Peripheral Interventions (PI) which include stents balloon catheters wires peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM) which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP) which include steerable RF ablation catheters intracardiac ultrasound catheters diagnostic catheters delivery sheaths and other accessories; Endoscopy which includes Spyglass System WallFlex Colonic Stents Resolution Clip and Expect Aspiration Needle among others; Urology and Womens Health and Neuromodulation.